Sly Saint
Senior Member (Voting Rights)
Tamara Carnac
This version is not peer-reviewed.
Abstract
Myalgic Encephalomyelitis (ME), sometimes known as Chronic Fatigue Syndrome (CFS), is a complex illness marked by fatigue, post-exertional malaise, cognitive dysfunction, autonomic instability, and immune abnormalities. This paper proposes a unifying hypothesis centred on dysfunction of lecithin–cholesterol acyltransferase (LCAT) and deficiency of phosphatidylcholine (PC), leading to altered membrane lipid composition, excess arachidonic acid release, and chronic inflammation. These changes may promote dysregulated production of prostaglandins and leukotrienes, imbalance in PPAR-γ activity, and disruptions in sex hormone metabolism, potentially contributing to conditions like polycystic ovary syndrome (PCOS), endometriosis and mast cell activation syndrome (MCAS). We propose that different combinations of LCAT dysfunction and PC deficiency result in distinct physiological subtypes. These include a neuronal insulin-hypersensitive subtype with reduced norepinephrine transporter (NET) expression and high extracellular norepinephrine; a high membrane arachidonic acid subtype with preserved PC but increased NET expression and neuronal insulin resistance; and a third group characterised by both elevated norepinephrine and downregulated β₂-adrenergic receptors. Each subtype presents with a different pattern of autonomic, metabolic, and immune dysregulation. Additional variation may arise from differences in acetylcholine synthesis, norepinephrine production capacity, and feedback mechanisms within the adrenergic system. This framework helps explain the heterogeneity of ME and offers a biologically coherent basis for further investigation into its pathophysiology.
A Systems Hypothesis: Reverse Cholesterol Transport Dysfunction, Arachidonic Acid Accumulation, and Noradrenergic Imbalance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[v3] | Preprints.org
This version is not peer-reviewed.
Abstract
Myalgic Encephalomyelitis (ME), sometimes known as Chronic Fatigue Syndrome (CFS), is a complex illness marked by fatigue, post-exertional malaise, cognitive dysfunction, autonomic instability, and immune abnormalities. This paper proposes a unifying hypothesis centred on dysfunction of lecithin–cholesterol acyltransferase (LCAT) and deficiency of phosphatidylcholine (PC), leading to altered membrane lipid composition, excess arachidonic acid release, and chronic inflammation. These changes may promote dysregulated production of prostaglandins and leukotrienes, imbalance in PPAR-γ activity, and disruptions in sex hormone metabolism, potentially contributing to conditions like polycystic ovary syndrome (PCOS), endometriosis and mast cell activation syndrome (MCAS). We propose that different combinations of LCAT dysfunction and PC deficiency result in distinct physiological subtypes. These include a neuronal insulin-hypersensitive subtype with reduced norepinephrine transporter (NET) expression and high extracellular norepinephrine; a high membrane arachidonic acid subtype with preserved PC but increased NET expression and neuronal insulin resistance; and a third group characterised by both elevated norepinephrine and downregulated β₂-adrenergic receptors. Each subtype presents with a different pattern of autonomic, metabolic, and immune dysregulation. Additional variation may arise from differences in acetylcholine synthesis, norepinephrine production capacity, and feedback mechanisms within the adrenergic system. This framework helps explain the heterogeneity of ME and offers a biologically coherent basis for further investigation into its pathophysiology.
A Systems Hypothesis: Reverse Cholesterol Transport Dysfunction, Arachidonic Acid Accumulation, and Noradrenergic Imbalance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[v3] | Preprints.org